These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29337201)

  • 1. On the glycosylation aspects of biosimilarity.
    Hajba L; Szekrényes Á; Borza B; Guttman A
    Drug Discov Today; 2018 Mar; 23(3):616-625. PubMed ID: 29337201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept.
    Borza B; Szigeti M; Szekrenyes A; Hajba L; Guttman A
    J Pharm Biomed Anal; 2018 May; 153():182-185. PubMed ID: 29499461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-glycan Analysis in Molecular Medicine: Innovator and Biosimilar Protein Therapeutics.
    Borza B; Hajba L; Guttman A
    Curr Mol Med; 2020; 20(10):828-839. PubMed ID: 33272172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host Cell Proteins: The Hidden Side of Biosimilarity Assessment.
    Mihara K; Ito Y; Hatano Y; Komurasaki Y; Sugimura A; Jones M; Liu H; Mai S; Lara-Velasco O; Bai L; Ketkar A; Adams M; Hirato T; Ionescu R
    J Pharm Sci; 2015 Dec; 104(12):3991-3996. PubMed ID: 26367379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review.
    Alsamil AM; Giezen TJ; Egberts TC; Leufkens HG; Vulto AG; van der Plas MR; Gardarsdottir H
    Eur J Pharm Sci; 2020 Nov; 154():105501. PubMed ID: 32739253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiating biosimilarity and comparability in biotherapeutics.
    Azevedo V; Hassett B; Fonseca JE; Atsumi T; Coindreau J; Jacobs I; Mahgoub E; O'Brien J; Singh E; Vicik S; Fitzpatrick B
    Clin Rheumatol; 2016 Dec; 35(12):2877-2886. PubMed ID: 27734233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparability study of Rituximab originator and follow-on biopharmaceutical.
    Montacir O; Montacir H; Eravci M; Springer A; Hinderlich S; Saadati A; Parr MK
    J Pharm Biomed Anal; 2017 Jun; 140():239-251. PubMed ID: 28371718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept.
    Montacir O; Montacir H; Springer A; Hinderlich S; Mahboudi F; Saadati A; Parr MK
    Protein J; 2018 Apr; 37(2):164-179. PubMed ID: 29411222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
    Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
    MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are biosimilars patentable?
    Rolfe D; Parker J; Morgan M
    Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.
    Nupur N; Chhabra N; Dash R; Rathore AS
    MAbs; 2018 Jan; 10(1):143-158. PubMed ID: 29200314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept.
    Cho IH; Lee N; Song D; Jung SY; Bou-Assaf G; Sosic Z; Zhang W; Lyubarskaya Y
    MAbs; 2016; 8(6):1136-55. PubMed ID: 27246928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications.
    Duivelshof BL; Jiskoot W; Beck A; Veuthey JL; Guillarme D; D'Atri V
    Anal Chim Acta; 2019 Dec; 1089():1-18. PubMed ID: 31627805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The road from development to approval: evaluating the body of evidence to confirm biosimilarity.
    Declerck P; Farouk Rezk M
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv4-iv13. PubMed ID: 28903545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycan characterization of biopharmaceuticals: Updates and perspectives.
    Planinc A; Bones J; Dejaegher B; Van Antwerpen P; Delporte C
    Anal Chim Acta; 2016 May; 921():13-27. PubMed ID: 27126786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF; Litten JB; Grampp G
    Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical Approaches to Assess Biosimilarity from Analytical Data.
    Burdick R; Coffey T; Gutka H; Gratzl G; Conlon HD; Huang CT; Boyne M; Kuehne H
    AAPS J; 2017 Jan; 19(1):4-14. PubMed ID: 27709452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms.
    Nupur N; Joshi S; Gulliarme D; Rathore AS
    Front Bioeng Biotechnol; 2022; 10():832059. PubMed ID: 35223794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.